Additionally, stable binding with effector molecules such as HO-1 (−8.0 kcal/mol) and Caspase-3 (−7.1 kcal/mol) provides preliminary in silico evidence that Engeletin might exert multitarget, multi-pathway regulatory effects in the context of ischemic stroke (Figure 6). The gene discussed is CASP3; the disease is ischemic stroke.